Markets - Research and Markets - RSS Feed

Generic and Innovative Drugs Markets in Central and Eastern Europe 2009

press@researchandmarkets.com — Wed, 25 Nov 2009 15:11:14 GMT

Generic and innovative drugs markets in Central and Eastern Europe 2009 - Comparative analysis, reimbursement policies and development forecasts 2009-2011 This report provides a study analysis of the eight generic and innovative drugs markets in the CEE: - Bulgaria, - Czech Republic, - Hungary, -...

Drug Price/Cost Debate: Coping with Escalating Pricing Pressures

press@researchandmarkets.com — Mon, 16 Nov 2009 12:08:01 GMT

Insinuations of profiteering were made against an H1N1 swine flu vaccine manufacturer in the summer of 2009 As the swine flu epidemic began to take on serious proportions, public scrutiny in the United Kingdom focused on manufacturers developing vaccines for the prevention of this disease and on...

China Asthma Drug Market Report 2008

press@researchandmarkets.com — Tue, 15 Sep 2009 15:27:52 GMT

According to the 2004 Global Burden of Asthma Report, there were about 300 million asthma patients worldwide One out of every 250 disease-related deaths was caused by asthma In China, the incidence rate of asthma patients has continuously increased in the recent years, especially among urban...

Emerging Trends in Active Pharmaceutical Ingredient Outsourcing

press@researchandmarkets.com — Tue, 04 Aug 2009 13:30:24 GMT

During the last 30 years the chemical manufacture of active pharmaceutical ingredients has been undergoing a transition from global pharmaceutical organisations back integrated to commodity chemical raw materials to organisations which focus on their key success drivers and outsource the necessary...

All Change in the Advanced Wound Care Market 2009

press@researchandmarkets.com — Mon, 08 Jun 2009 09:19:52 GMT

The rapid progress of The Npwt Sector and the exit of Johnson & Johnson and Bristol-Myers Squibb has changed this sector fundamentally Who are the players And technologies that are benefiting from these developments? Key Areas Addressed: - Growth forecasts to 2013 for the major moist wound care,...

European Diabetes Diagnostics Market

press@researchandmarkets.com — Wed, 03 Jun 2009 09:02:17 GMT

This strategic analysis service provides a detailed analysis of the European diabetes diagnostics market An in-depth analysis of marketing parameters (revenues, forecasts, geographic trends and market share) coupled with competitive factors and strategies for sustained market prevalence are reported...

Manufacturing of Pharmaceutical Proteins: From Technology to Economy

press@researchandmarkets.com — Wed, 18 Mar 2009 12:38:06 GMT

This comprehensive introduction covers all aspects of biopharmaceutical manufacturing, including legal and regulatory issues as well as costing procedures Written by a leading expert at one of the largest pharmaceutical companies worldwide, this practical text is aimed at a wide audience, ranging...

Global Spine Market Report: 2009 Edition

press@researchandmarkets.com — Wed, 11 Feb 2009 10:15:10 GMT

Spinal implant market, one of the largest markets in orthopedics, is being driven by favorable demographic trends and high incidence of back pain In the US, the occurrence of lower back pain at some time in one’s lifetime is almost ninety percent Technological advances such as minimal invasive...

Global Intravenous (IV) Iron Drugs Market: Potential Opportunities

press@researchandmarkets.com — Wed, 11 Feb 2009 09:58:34 GMT

Iron deficiency anemia or IDA is among one of the top ten most important public health issues, according to the World Health Organization With approximately one-third of the current global population facing the problem of iron deficiency, more and more people are likely to suffer from a lack of iron...

Emerging Blockbusters: 2009's Most Promising Drugs and the Future of the Blockbuster Model

press@researchandmarkets.com — Wed, 07 Jan 2009 15:28:17 GMT

Introduction In 2007, 93 blockbuster drugs (drugs with more than $1 billion in annual sales) were on the market and generated more than $220 billion in revenue These high-value products are fundamental to the success and growth of the pharmaceutical industry and the number of blockbusters on the...

Pharmaceutical New Product Commercialization: Preparing for Market Success

press@researchandmarkets.com — Mon, 17 Nov 2008 15:12:23 GMT

Long and costly product development cycles make it essential for pharmaceutical companies to maximize limited staff and resources to the development of compounds with the greatest potential market value From the time a company’s R&D (Research and Development) group begins to develop a new...

Latin American Rheumatoid Arthritis Drugs Market

press@researchandmarkets.com — Tue, 04 Nov 2008 10:16:56 GMT

This study provides a comprehensive overview of the Latin American rheumatoid arthritis drugs market Researched countries encompass Brazil and the Southern Cone (Chile and Argentina) Included are competitive profiles, distribution network discussions, pricing analysis, drug pipelines, regulatory...

Pharmaceutical Market in Ukraine 2008: Development Forecasts for 2008 - 2010

press@researchandmarkets.com — Tue, 21 Oct 2008 10:16:26 GMT

Pharmaceutical market in Ukraine 2008 is an invaluable compendium of market information and data that enables any company to make educated decisions and to take views about the potential of the pharmaceutical sector in Ukraine Our report paints a comprehensive portrait of the Ukrainian...

Successful Pharmabiotech Alliance Strategies: Driving Synergies, Avoiding Failure and Managing Relationships

press@researchandmarkets.com — Fri, 17 Oct 2008 08:58:39 GMT

Over the past few years, Business Insights has noted that alliances between pharmaceutical (“pharma”) and biotechnology (“biotech”) companies have become common, with hundreds of relationships currently in place to develop drugs for virtually all of the highest priority conditions For pharmaceutical...

U.S. Sales Communications Excellence: Resources, Structure and Processes to Optimize Pharmaceutical Sales Communications

press@researchandmarkets.com — Thu, 16 Oct 2008 09:18:00 GMT

Sales force performance significantly impacts growth and bottom line results The ability of senior management to effectively disseminate vital information to their sales forces while maximizing selling time is integral to the overall success of all pharmaceutical and biotech companies The objective...

Maintaining a Competitive Edge in Pharmaceutical Public Affairs: Benchmarking the Resources Required to Serve the U.S. Market

press@researchandmarkets.com — Thu, 16 Oct 2008 08:38:12 GMT

To ensure organizational health and competitiveness, companies must continually identify optimal resource levels for their operations This benchmark study was designed to collect key staffing and investment benchmarks for U S based pharmaceutical Public Affairs functions Data from this study will...

Diabetes Market Forecast to 2013

press@researchandmarkets.com — Wed, 15 Oct 2008 13:33:28 GMT

Cutting Edge Information is proud to present a new report on the Diabetes market titled "Diabetes Market Forecast to 2013 " Which companies are poised to dominate the diabetes market? With new classes on the rise, which innovative therapies will make an impact? How will clinical results and safety...

U.S. Stem Cell Market - Current Developments

press@researchandmarkets.com — Thu, 09 Oct 2008 15:19:46 GMT

This research service covers the U S stem cell market and current developments Included are disease overviews for main indications, estimated patient penetration for main indications, technology trends, and total market potential The market is segmented by cell type: adult stem cell and embryonic...

Pharmaceutical Pricing and Reimbursement in Spain, 2008

press@researchandmarkets.com — Fri, 19 Sep 2008 08:14:17 GMT

In recent years, Spain has rapidly increased its spending on healthcare, and pharmaceuticals account for a larger share of healthcare expenditures in Spain than in most other European countries However, Spanish drug prices are among the lowest in Europe and have been eroded by repeated mandatory...

Key Markets in Medicare Part D

press@researchandmarkets.com — Fri, 19 Sep 2008 08:01:06 GMT

Medicare Part D, the outpatient prescription drug benefit introduced in January 2006, had an immediate impact on the U S pharmaceutical market and now accounts for almost one-fifth of prescription drug sales Cardiovascular diseases, metabolic disorders, infectious diseases, immune/inflammatory...

The Automated Microbiology Market: A Worldwide Strategic Analysis: United States

press@researchandmarkets.com — Thu, 18 Sep 2008 08:45:57 GMT

The study explores future marketing and technological trends in US; provides estimates of the specimen and test volumes, instrument placements, sales and market shares through the year 2016; compares features of major analyzers; and profiles Key Topics Covered: - Business trends with significant...

The Automated Microbiology Market: A Worldwide Strategic Analysis: United Kingdom

press@researchandmarkets.com — Thu, 18 Sep 2008 08:39:24 GMT

The study explores future marketing and technological trends in UK; provides estimates of the specimen and test volumes, instrument placements, sales and market shares through the year 2016; compares features of major analyzers; and profiles Key Topics Covered: - Business trends with significant...

The Automated Microbiology Market A Worldwide Strategic Analysis: Spain

press@researchandmarkets.com — Thu, 18 Sep 2008 08:33:05 GMT

The study explores future marketing and technological trends in Spain; provides estimates of the specimen and test volumes, instrument placements, sales and market shares through the year 2016; compares features of major analyzers; and profiles Key Topics Covered: - Business trends with significant...

Supply Chain Management in Pharmaceutical Industry in Poland 2008

press@researchandmarkets.com — Tue, 16 Sep 2008 11:35:30 GMT

Supply chain management in the pharmaceutical industry in Poland 2008 thoroughly examines the most innovative ways of gaining competitive advantage in the pharmaceutical sector It studies the conditions and the level of advancement of the Supply Chain Management on the Polish market in the context...

Supply Chain Management in Pharmaceutical Industry in Poland 2008

press@researchandmarkets.com — Tue, 16 Sep 2008 11:35:30 GMT

Pharmacy Liberalisation in Europe: Prospects and Implications

press@researchandmarkets.com — Tue, 16 Sep 2008 11:09:31 GMT

Very little in the pricing environment in Europe is predictable to pharmaceutical companies and only rarely is much notice given of change But before the end of 2009, if the European Court of Justice accepts the arguments put to it forcefully by the European Commission and by DocMorris, then...

Business Development: Accelerating the Deal

press@researchandmarkets.com — Tue, 09 Sep 2008 14:14:42 GMT

Close key deals and build a top-flight business development team in this report from Cutting Edge Information: Deal-making is an established strategy for filling company pipelines, raising cash, expanding portfolios and driving long-term revenue Whether companies forge straightforward licensing...

Cardiovascular Biomarkers: Players, Products and Prospects (Volume III)

press@researchandmarkets.com — Fri, 05 Sep 2008 10:49:32 GMT

Part of our new 3-volume report on Cancer, CNS and Cardiovascular Biomarkers, this volume provides a comprehensive analysis of the cardiovascular biomarker sector, along with a critical assessment of the companies involved In 2007, the cardiovascular biomarker market accounted for an estimated 23%...

CNS Biomarkers: Players, Products and Prospects (Volume II)

press@researchandmarkets.com — Fri, 05 Sep 2008 10:28:15 GMT

Part of our new 3-volume report on Cancer, CNS and Cardiovascular Biomarkers, this volume provides a comprehensive analysis of the CNS biomarker sector, along with a critical assessment of the companies involved By 2015, we estimate the global CNS biomarker market will account for around 15% of...

Cancer Biomarkers: Players, Products and Prospects (Volume I)

press@researchandmarkets.com — Fri, 05 Sep 2008 10:10:20 GMT

Part of our new 3-volume report on Cancer, CNS and Cardiovascular Biomarkers, this volume provides a comprehensive analysis of the cancer biomarker sector, along with a critical assessment of the companies involved The cancer biomarker market represents one of the largest segments of biomarkers in...

Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects

press@researchandmarkets.com — Fri, 05 Sep 2008 09:50:07 GMT

By 2015, the biomarker market is forecast to be worth over US$20 billion as the cardiovascular and CNS biomarker market segments begin to mature with the launch of a number of diagnostic tests to guide the treatment of neuropsychiatric and neurodegenerative diseases This new 3-volume report provides...

Indian Pharma Industry Monitor

press@researchandmarkets.com — Mon, 01 Sep 2008 12:00:04 GMT

The Indian Pharma Review gives a summary and analysis of the Indian pharma market including, mergers, acquisitions, divestments, major pharma deals and strategic collaborations, clinical trial highlights, and pipeline advancements during April-June, 2008 The report also contains a brief financial...

Global Pharma Industry Monitor

press@researchandmarkets.com — Mon, 01 Sep 2008 11:16:08 GMT

The Global Pharma Industry Monitor gives a quarterly summary and analysis of the global pharma market including, mergers, acquisitions, divestments, major pharma deals and strategic collaborations, clinical trial highlights, and pipeline advancements The report also provides a comprehensive review...

The Automated Microbiology Market A Worldwide Strategic Analysis: Japan

press@researchandmarkets.com — Thu, 28 Aug 2008 10:32:27 GMT

The study explores future marketing and technological trends in Japan; provides estimates of the specimen and test volumes, instrument placements, sales and market shares through the year 2016; compares features of major analyzers; and profiles Key Topics Covered: - Business trends with significant...

The Automated Microbiology Market A Worldwide Strategic Analysis: Italy

press@researchandmarkets.com — Thu, 28 Aug 2008 10:18:11 GMT

The study explores future marketing and technological trends in Italy; provides estimates of the specimen and test volumes, instrument placements, sales and market shares through the year 2016; compares features of major analyzers; and profiles Key Topics Covered: - Business trends with significant...

The Automated Microbiology Market A Worldwide Strategic Analysis: Germany

press@researchandmarkets.com — Wed, 27 Aug 2008 11:52:36 GMT

The study explores future marketing and technological trends in Germany; provides estimates of the specimen and test volumes, instrument placements, sales and market shares through the year 2016; compares features of major analyzers; and profiles Key Topics Covered: - Business trends with...

The Automated Microbiology Market A Worldwide Strategic Analysis: France

press@researchandmarkets.com — Wed, 27 Aug 2008 11:43:05 GMT

The study explores future marketing and technological trends in France; provides estimates of the specimen and test volumes, instrument placements, sales and market shares through the year 2016; compares features of major analyzers; and profiles Key Topics Covered: - Business trends with significant...

Pharmaceutical Pricing and Reimbursement News in the Second Quarter of 2008

press@researchandmarkets.com — Wed, 20 Aug 2008 08:37:22 GMT

The United States stands in stark contrast to Europe and Japan in terms of the freedom that manufacturers have to set—and increase—the prices of branded drugs in the U S market However, pharmaceutical companies need to give careful thought to their pricing strategies in all markets Payers around the...

Dealmaking and Financing: Mergers and Acquisitions in Key Markets

press@researchandmarkets.com — Mon, 18 Aug 2008 10:16:57 GMT

Billion-dollar deals Hostile takeovers Reverse mergers Bidding wars All of these are signs that Big Pharma is hungry for deals and is aggressively seeking, assessing, and consummating alliances on several fronts No facet of the biotech, specialty, or generics industries is being ignored; no...

Improving Return on Investment in Pharmaceutical Marketing

press@researchandmarkets.com — Mon, 18 Aug 2008 08:08:25 GMT

This report on improving the return on investment in pharmaceutical marketing is the third 2008 report published in our new Executing Change Series This series looks at an event, business practice, or strategy that is changing the pharmaceutical or biotechnology industries and examines the...

The Automated Microbiology Market: A Worldwide Strategic Analysis: A 7-Country Market Survey

press@researchandmarkets.com — Wed, 13 Aug 2008 09:10:49 GMT

The study explores future marketing and technological trends in US, Europe and Japan; provides estimates of the specimen and test volumes, instrument placements, sales and market shares through the year 2016; compares features of major analyzers; and profiles Key Topics Covered: - Business trends...

Access to Hospital Pharmaceutical Markets in the United Kingdom

press@researchandmarkets.com — Tue, 12 Aug 2008 15:12:57 GMT

Public hospitals represent a very important market segment for most biopharmaceutical companies in Europe They are the often the only market for the increasing numbers of specialty products emerging from R&D, with many primary care products also unable to get established for maintenance therapy in...

Institutional Pharmacies Market Overview 2007

press@researchandmarkets.com — Fri, 25 Jul 2008 13:53:57 GMT

Institutional pharmacy describes the range of services provided by pharmacists to residents of nursing homes, hospitals, or hospice environments In their role as medication therapy experts, institutional pharmacists take responsibility for their patients' medication-related needs; ensure that their...

Competitor Analysis: Erythropoietin (EPO)

press@researchandmarkets.com — Tue, 22 Jul 2008 13:22:13 GMT

The Competitive Intelligence Report Erythropoiesis Stimulating Agents (ESA) as of July 2008 in its 4th edition provides information on the market size of erythropoietin products in 2007, an overview on existing first and second generation epoetin products on the market, a compilation of first...

Biopharmaceuticals in South East Asia

press@researchandmarkets.com — Thu, 10 Jul 2008 10:59:02 GMT

This detailed report analyses the market and research environments, assessing risk and identifying opportunity in Indonesia, Malaysia, Singapore, South Korea, Taiwan and Thailand Providing: - A thorough review of the burgeoning market for biopharmaceutical drugs in South East Asia - An examination...

Pharmaceutical Competitive Intelligence: Expanding the Role and Reach of CI

press@researchandmarkets.com — Mon, 23 Jun 2008 13:11:18 GMT

Pharmaceutical competitive intelligence (CI) helps drive decision-making processes across an organization As a forward-thinking, proactive support function, CI influences business development and brand management, among other areas CI identifies market risks as well as business growth opportunities...

Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market

press@researchandmarkets.com — Mon, 26 May 2008 11:20:44 GMT

Introduction Although the obsessive-compulsive disorder (OCD) market is small and OCD diagnosis rates are low, this market is characterized by substantial unmet need and commercial opportunity Companies looking to expand their agents into this market need to explore unconventional strategies that...

A Product Director’s Guide to Promotional Mix

press@researchandmarkets.com — Fri, 04 Apr 2008 15:46:32 GMT

Uncover real-world brand budgets from the first three years on the market: Explore marketing budgets for 9 brands throughout their first, second and third years of market availability Each easy-to-navigate brand profile walks you through annual spending in three critical areas of product management:...

A Guidebook to Pharma Brand Optimization: Lifecycle Management Strategy

press@researchandmarkets.com — Tue, 01 Apr 2008 14:56:17 GMT

Increase the effectiveness of your LCM Strategies: With pipelines diminishing and generics becoming more aggressive, pharmaceutical companies must maximize their brands’ value and time on the market Strategic and well-orchestrated lifecycle management efforts are crucial to maintaining a brand’s...

Indian Generics, 2008-2012: The Growing Threat to Westernised Markets

press@researchandmarkets.com — Fri, 28 Mar 2008 16:00:13 GMT

Indian pharmaceutical companies are grabbing headlines on an almost daily basis and are increasingly carving out market shares for themselves in the US and many other markets around the world Several leading Indian pharmaceutical companies have applied themselves to the challenge of entering Western...

Global Biopharmaceutical Contract Manufacturing Markets

press@researchandmarkets.com — Wed, 23 Jan 2008 15:57:12 GMT

This research service provides revenue and capacity forecasts for biopharmaceutical CMOs globally, by product type and region It also provides growth drivers, market trends and a cost analysis...

European Immunochemistry Analysers Markets

press@researchandmarkets.com — Tue, 22 Jan 2008 16:55:14 GMT

This Frost & Sullivan research service titled European Immunochemistry Analysers Markets provides an overview of immunochemistry analysers with their revenues It provides a complete analysis of key market drivers, restraints and trends in the market Finally, it provides strategic solutions that...

Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs

press@researchandmarkets.com — Tue, 08 Jan 2008 14:33:24 GMT

The market for lifestyle drugs has become one of the most dynamic and commercially attractive sectors in the pharmaceutical industry With developed markets expected to witness aging demographics as well as continued increases in health awareness, disposable incomes and pharmaceutical branding...

Pharmaceutical Regulatory Affairs in the EU & US

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:22 GMT

This report will enable you to implement a regulatory strategy that will guide your product from development to launch, in both the EU and US.

- Discover the origins and purposes of pharmaceutical regulation, and the principal regulatory bodies. Appreciate how they affect your role as a regulatory affairs professional

- Know how to ensure your pre-clinical and clinical studies comply with key EU and US regulations, including GLP, GCP, the EU Clinical Trials Directive and FDA requirements

- Learn the fundamental procedures, issues and initiatives (including the FDA Critical Path) that will have an impact on your regulatory strategy

- Gain awareness of other procedures so you can manage the approval process for a range of product types (including biosimilars, generics and variations).

Regulation affects all aspects of the pharmaceutical world, from independent innovators and pharmaceutical companies, to regulatory and administrative bodies, and most importantly, to the patients taking the medicines. This report provides an introduction to the world of regulatory affairs, describing the history behind the need to regulate medicines for human use and the key events helping to shape this.

In Chapter 1, there is an overview of EU regulation, outlining how it has transformed into the large, 25-country structure it is today. Ensuring that such a vast amount of countries regulate medicines in the same way is an immense task for the EU’s regulatory and government bodies, and is explained in the later part of this chapter. It also provides an insight into the regulatory structures in place, the methods of regulating and some of the more important legislation adopted to achieve this.

Finally, the role of the Regulatory Professional is explained, enabling the reader to understand how they fit into the whole process of pharmaceutical regulation. Although it is unlikey that a professional would tackle all aspects of regulatory affairs, it is still important to understand

EU Paediatric Medicines Regulation: Boon or Burden?

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:22 GMT

Draft EU regulations on paediatric medicines were approved by the European Parliament on 1 June 2006. It came into force on 26 January 2007.

It is estimated that between 50-90% of medicines used to treat children have never been specifically studied in or approved for the paediatric population. Through a combination of obligations and incentives, the proposed regulation aims to ensure that:

- paediatric medicines are subject to high-quality research and clinical development, while avoiding any unnecessary clinical trials in children;
- the resulting products are duly authorised across the EU;
- there is more information on the use of medicines developed specifically for children and more transparency in paediatric clinical trials.

In particular, the new regulations will provide incentives to develop paediatric forms and doses of medicines currently only approved for adults, the main one being a six-month extension to patent protection for innovator companies that test their products on children.

There will also be a separate paediatric marketing authorisation for off-patent medicines that are developed for children and a special fund to encourage research into paediatric forms of such products. The regulation also sets up a paediatric committee at the European Medicines Agency that will agree paediatric investigation plans with companies and determine research priorities.

The R&D-based industry believes the regulation would allow Europe to reclaim a central role in innovative drug development. It is less popular with the generics community. Last minute amendments, negotiated behind the scenes at the European Parliament, mean that during a five-year transition period, innovator companies have up to 6 months before expiry to submit the data and apply for the extension. The original draft suggested a two-year deadline. This change is likely to dramatically affect the timing of generic entry. It is also likely to pose issues for some Eastern European states who

Pricing & Reimbursement in Asia-Pacific

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:22 GMT

Pricing & Reimbursement in Asia Pacific details the reimbursement situation in all major markets in the region. It is designed as a comprehensive guide to what pharmaceutical companies needs to know to ensure that its products are reimbursed by the appropriate government agency or health insurer.

Each country chapter details who is responsible for reimbursement, the processes for assessing a drug’s suitability for reimbursement in that country, recent changes, government policy on healthcare costs and expected changes in the near future.

This new report will provide you with:
- An overview of the reimbursement procedures in Asia Pacific
- Information on payment bodies
- An outline of the recent changes to reimbursement regulation
- Government policy
- Generic substitution
- Predictions of future reforms to enable you to develop future strategy

Vaccines Market Insight: Products, Pipelines & Market Outlook

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:20 GMT

This report examines the latest developments in the vaccine industry with particular emphasis placed on the role of vaccines in the prevention and treatment of cancer. It includes an overview of the immune system, an outline of how immunisation works and an assessment of how different types of vaccine work with that system. The report looks in particular at the suitability of cancer as a target for the next generation of vaccines.

The report examines the size and value of the vaccine market as it is today. This includes a full discussion of the vaccines that have reached the marketplace, including the first cancer vaccines. The vaccine market is currently dominated by a handful of pharmaceutical companies and these are also discussed.

The vaccine industry faces numerous opportunities as its understanding of the immune system grows, increasing both the number of vaccines in development and the range of suitable indications to target. However, there are also serious challenges that must be overcome: developers and manufacturers face technical and commercial challenges.

The report includes a full discussion of the many vaccines currently in development, focusing on those for cancer and for other unmet needs. The report concludes with profiles of the pharmaceutical and biotechnology companies that are actively developing cancer vaccines, as well as the major players in the vaccine market as a whole.

The report provides:
- an overview of the immune system - enables an understanding of how vaccines have worked in the past and how an increasing knowledge of how - the immune system works is affecting the types of vaccine currently in development.
- a discussion of the immunological aspects of cancer
- a summary of the types of vaccines available
- a discussion of the vaccines market - how important cancer vaccines are and an assessment of the size of the market
- a complete guide to the current vaccines on the market - background on the indications targeted by these

How to React to Parallel Trade

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:18 GMT

Parallel trade is now very much a part of the European pharmaceutical landscape. And as such you cannot avoid at some point being affected by it. It is essential, therefore, that you learn how to deal with it so you can begin implementing counter measures to minimise the risk it poses to your profitability.

This report tells you everything you need to know about parallel trade and provides expert advice on what you can do to tackle it.

This report provides:

- a complete and independent overview of parallel trade, which explains the complex economic, legal and regulatory aspects involved, so you can assess the potential impact it may have on your profitability
- a clear and comprehensive guide to the legal and regulatory issues that surround parallel trade, enabling you to get to grips with this complex area more quickly
- key market profiles, detailing the regional variations that provide the perfect environment for parallel trade to thrive so you can understand, country to country, how this affects the industry
- profiles of leading parallel importers - so you can build a thorough understanding of the companies involved and their activities
- expert guidance on how to respond strategically to parallel trade - discover how you can combat parallel trade and cut the risk to your bottom line
- an exploration of the future prospects for parallel trade - so you can prepare for the future and be ready to pre-empt the parallel traders next steps.

About the author:

From 2001-2005, Donald Macarthur was Secretary General of the European Association of Euro-Pharmaceutical Companies (EAEPC), the pan-European grouping of national associations and individual firms involved in parallel trading of medicines with membership from 16 EEA countries.

During the preceding 16 years he was an independent consultant and analytical writer on global pharmaceutical business issues. He has produced 40+ reports and his consultancy clients have included the European Federation of

A Guide to Biosimilars, Biogenerics and Follow-On Biologics

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:18 GMT

This report will give readers a broad overview of the key drivers and players involved in the biosimilars revolution today. It will also arm readers with the strategic information they need to face the new opportunities presented by this market trend, as well as its challenges.

With regulation playing a key role in the evolving landscape for biosimilar products, the report places particular emphasis on the regulatory situation in two of the largest markets; the US and Europe. While the European regulatory framework for biosimilars is more defined, there have been significant developments in the US too, notably the FDAs approval of Omnitrope, which demostrated that the simplified approval process is available to biosimilars that demostrate comparability with biologics regulated under NDAs. The report discusses the various factors at play in these two markets.

It analyses the situation from the perspectives of both biosimilar manufacturers and innovator companies. For firms looking to develop biosimilars, some 75 proteins and peptide therapeutics were recently identified as potential profitable targets for new products. And significantly, a substantial proportion of these were approved as NDAs, meaning that biosimilar firms can target them knowing that a clear regulatory pathway exists.

Originator companies, meanwhile, are looking to use a range of strategies to delay biogeneric competition; these strategies include patenting preferred formulations, manufacturing methods and protein modifications.

The report will spotlight the most prominent companies in the biosimilars field, not only the well established generics manufacturers but emerging biosimilar developers too. It will also assess the various geographical markets for therapeutic proteins, including North America, Europe and Brazil.

Use this report provides:
- an overview of the market for therapeutic proteins, including growth factors, anticoagulants, insulins, interferons, hormones, enzymes and vaccines

Pharmaceutical Pricing and Reimbursement: Strategies for Market Access Across the US, Europe, Japan and Other Key Geographies

press@researchandmarkets.com — Mon, 17 Dec 2007 16:39:35 GMT

The global pharmaceutical pricing and reimbursement environment is notoriously complex and continuously changing Pharma companies must implement strategic pricing assessments across global markets and product lifecycle phases in order to develop effective pricing policies By incorporating such...

The Gastrointestinal Market Outlook to 2012

press@researchandmarkets.com — Fri, 30 Nov 2007 16:22:46 GMT

Gastrointestinal tract disorders (GIT) are a prominent component in the overall disease burden of the world’s most developed economies, and a lack of effective long-term treatments and limited etiological understanding is continuing to exacerbate the impact of such conditions As the GIT Market...

Pricing and Reimbursement Issues for Immune Disease Therapies

press@researchandmarkets.com — Thu, 01 Nov 2007 12:49:12 GMT

Introduction Within major international pharmaceutical markets, drug therapies for immune disorders span an enormous price range—from a few cents per day to tens of thousands of dollars per year Not surprisingly, payers impose restrictions on the use of the most expensive agents, especially the...

Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff

press@researchandmarkets.com — Wed, 17 Oct 2007 08:31:48 GMT

Introduction This report provides a comprehensive strategic analysis of the mAb market out to 2012 by company It identifies four established and four emerging players within the mAb sector which are forecast to play the most commercially significant role within this market The report assesses how...

Emerging Pharmaceutical Markets: Growth Opportunities, Changing Healthcare Dynamics and Regulatory Trends

press@researchandmarkets.com — Thu, 27 Sep 2007 15:35:23 GMT

The growth of emerging pharmaceutical markets remains impressively buoyant, having attained a 14 7% value increase over the 2005-06 period, a substantially greater rate than those witnessed within the developed markets of the EU and US Although emergent markets proffer access to sizeable patient...

European Interventional Radiology Markets

press@researchandmarkets.com — Tue, 25 Sep 2007 14:10:45 GMT

Technological Advances Promote Growing Use of Interventional Radiology Technological innovations that support more sophisticated and rapid imaging are progressively widening the application area of interventional radiology and boosting market expansion Recent advances in imaging technology offer...

Advanced Wound Management Markets in South Korea

press@researchandmarkets.com — Tue, 25 Sep 2007 13:35:45 GMT

Acute Wound Care to Grow at Faster Pace than Chronic Wound Care As one of the most developed Asian countries, South Korea has a well-established healthcare infrastructure and high per capita healthcare expenditure It also has a strong National Healthcare Insurance (NHI) program These factors make it...

China Pharmaceutical Industry Report 2006-2007

press@researchandmarkets.com — Fri, 14 Sep 2007 08:51:15 GMT

In Jan-Feb 2007, Product sales revenue of China pharmaceutical industry rose by 17.8% year-on-year and, the gross profits increased by 29.6% from a year earlier.

It is noteworthy that the sales of chemical raw material medicine kept a fast growth and so did the Chinese traditional patent medicine. With the rising price of raw material medicine, the profit also grew rapidly. Besides, there is a sharp increase in the profit of chemical medicine and Chinese traditional patent medicine. Only the growth of the profit of biological medicine was slightly lower than that of the same period of 2006. Except for chemical preparation medicine, the profit margin of each subsidiary industry was all below the level of the year 2006 around, but higher than the same period of last year.

China Medicated Health Product Industry Report 2007

press@researchandmarkets.com — Fri, 14 Sep 2007 08:51:10 GMT

Its estimated that in the forthcoming couple of years, the growth rate of the sales income of the medical industry will remain at 15-17%. In the long term, thanks to the highest growth speed, Chinas medical market will become the worlds 7th largest market in 2010 and the 2nd in 2020, only behind America.

Compared with developed countries like America, Chinas current medical enterprises have small scales, unapparent product differentiation and low industrial concentricity. They are facing low-level but furious competition.

At present, there are over 1000 healthcare product enterprises in China, generating the annual sales value of RMB 50 billion and growing by 15-20% yearly. Due to the continuously issued regulation policies as well as high barriers of direct marketing policies, the concentration degree of the healthcare industry will be remarkably improved. By virtue of its competitive advantages, Chinese traditional healthcare products will take a critical position in the industry in the future.

China Anti-tumor Drugs Market Report 2007

press@researchandmarkets.com — Fri, 14 Sep 2007 08:51:09 GMT

The anti-tumor drugs market operated well in 2006, and the total sales volume amounted to USD 34.6 billion, up 20.5% from a year earlier, and the growth margin ranked the first place among all the treatment categories to be the most important drive force for promoting the global drugs market. According to the increase trend in recent five years, it is forecasted that the anti-tumor drugs will probably be the unit product with the largest sales income in the global drugs market.

According to the forecast of IXIS, the molecule-targeted drugs will stand out singly, its annual compound growth rate (ACGR) will reach 23% in 2005-2010, and the market share will be from 39% in 2005 to 53.6% in 2010.

The total sales of anti-tumor drugs (except traditional Chinese medicine) in China amounted to RMB 6.002 billion in 2006, up 23.94% year-on-year. It is forecasted that the total sales of anti-tumor drugs (except traditional Chinese medicine) in China will reach RMB 7.6 billion in 2007, rising above 25% from a year earlier.

China Pharmaceutical Industry Report, 2006-2007

press@researchandmarkets.com — Fri, 14 Sep 2007 08:20:49 GMT

China Medicated Health Product Industry Report, 2007

press@researchandmarkets.com — Fri, 14 Sep 2007 08:20:44 GMT

China Anti-tumor Drugs Market Report, 2007

press@researchandmarkets.com — Fri, 14 Sep 2007 08:20:44 GMT

European Testosterone Replacement Therapies Markets

press@researchandmarkets.com — Wed, 29 Aug 2007 13:41:06 GMT

This Frost & Sullivan research service on the European Testosterone Replacement Therapies Market provides an overview of current treatment options, detailed analysis of the market, technological advancements and revenues of the market along with a complete analysis of key market drivers, restraints...

Sector Snapshot: Statin Drug Markets

press@researchandmarkets.com — Wed, 22 Aug 2007 15:00:44 GMT

The "Sector Snapshot" is designed to provide a high-level overview of a particular market sector, including key players, sales data and emerging trends This sector snapshot covers the demand and market size of statins for lowering cholesterol This snapshot also details world and U S statin market...

European Urinary Incontinence Therapeutics Markets

press@researchandmarkets.com — Tue, 24 Jul 2007 16:04:25 GMT

This Frost & Sullivan research titled European Urinary Incontinence Therapeutics Markets provides an overview of the current treatment options in the markets The study offers a detailed analysis of the key drivers, restraints, trends and the technological advances in the markets In this research,...

The Global Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape

press@researchandmarkets.com — Thu, 28 Jun 2007 14:15:46 GMT

The global anti-infective market is currently valued at US$66 5 billion with antiviral agents accounting for 24% of sales (excluding vaccines which target viral infectious diseases) According to our new report The Antivirals Market: R&D Pipelines, Markey Analysis and Competitive Landscape, the...

Drug Repositioning Strategies: Innovative Strategies to Boost Pipeline Productivity

press@researchandmarkets.com — Thu, 07 Jun 2007 15:42:40 GMT

Report overview Key findings Drug repositioning is regarded as the pharma industry’s solution to falling R&D productivity and weakening product pipelines, successful repositioned drugs such as raloxifene (Evista; Lilly), thalidomide (Thalomid; Celegene), (Exubera;Pfizer/Nektar) have...

Stakeholder Opinions: Fibromyalgia - Potentially Lucrative Market Soon To Become Reality

press@researchandmarkets.com — Mon, 28 May 2007 15:33:01 GMT

Mainly affecting women, fibromyalgia syndrome affects six million people in the US alone. This relatively common yet poorly understood syndrome is characterized by widespread muscle pain and fatigue and remains substantially underserved by the medical profession and the pharmaceutical industry. Currently, there are no drugs licensed to treat fibromyalgia in the US, Japan or Europe.

Scope of this title:

Analysis of the patient potential, main unmet needs, and clinical trial design in fibromyalgia, with an estimation of market size. Insight into current treatment controversies, including referral and prescribing patterns across the seven major markets. Detailed profiles of Cymbalta, Lyrica, and milnacipran for use in fibromyalgia, with indication-specific sales forecasts of these drugs to 2016. Discussion of key fibromyalgia market drivers, such as strategies that improve public awareness and physician education.

Highlights of this title:

Following FDA approvals, we foresee a dramatic rise in market value resulting from an upsurge in diagnosis and treatment rates. Estimated at $367m in 2006 in the US and 5EU, the market is forecast to grow to $1.7 billion in 2016. Commercial success of new fibromyalgia brands will encourage other companies to consider investment, and will see the R&D pipeline for new therapies increase over the coming years. A defined regulatory pathway will also attract future investors. Polypharmacotherapy will become commonplace in fibromyalgia management and Lyrica with Cymbalta will be a popular combination. This is good news for Lilly and Pfizer as it will effectively expand their market by reducing competition.

Reasons to order your copy:
Quantify the future market size in order to weigh up the risk of investing in fibromyalgia or to validate internal forecasts for pipeline products. Gain insight into opinion leaders thoughts on the major opportunities and challenges facing the fibromyalgia market. Assess the six major market (US and 5EU)

Sabinsa Case Study: Successfully Marketing Weight-Loss Supplements

press@researchandmarkets.com — Mon, 28 May 2007 15:32:55 GMT

This report on Sabinsa forms part of the case studies series, which explores business practices across a variety of disciplines and business sectors. Each case study provides a concise evaluation of a company that stands out in some area of its strategic operations.

Reasons to order your copy:
Gain insight into the methods used by important industry players to give them a competitive edge Identify specific areas for operational improvements Capitalize on the knowledge of experienced companies when entering a new niche or market

Pharmacoeconomics and Health Outcomes: Driving Formulary Access and Reimbursement

press@researchandmarkets.com — Wed, 23 May 2007 15:49:27 GMT

Examine pharmacoeconomics and health outcomes budgets, structures and strategies: With ever-increasing pressures from managed care organizations, government agencies, pharmacy benefit managers and other reimbursement groups for pharmaceutical companies to prove their products’ value,...

Pharmaceutical Product Relaunch: Preserving Market Share through Line Extension and New Market Entry Strategies

press@researchandmarkets.com — Wed, 23 May 2007 15:26:00 GMT

Uncover the decisions, investments and timing behind successful relaunch strategies: Product teams must begin their relaunch planning early to incorporate it into a strong overall lifecycle management strategy As product teams enter Phase 2 of development for their initial launch, they are often...

Pipeline Insight: Osteoporosis - Intermittent Dosing Drives Market Growth

press@researchandmarkets.com — Fri, 27 Apr 2007 11:06:22 GMT

The long-standing unmet need of the osteoporosis market has been for improved adherence to treatment Two pipeline products, Amgens Denosumab and Novartis Aclasta (zoledronate), have answered this demand with intermittent dosing schedules and consequently are expected to generate blockbuster revenues...

Pricing & Reimbursement Series: Medicare Part Ds Progress So Far

press@researchandmarkets.com — Fri, 27 Apr 2007 11:06:19 GMT

The roll-out of Part D in January 2006 represented a significant leap forward, since it provided coverage for outpatient drugs for Medicare patients for the first time. A high number of both patients and insurance providers are now involved in the program, as a result of strong patient enrollment.

Scope of this title:
Overview of Part D enrollment, plus an analysis of how it has impacted the healthcare insurance market, and the branded and generic drug environment Analysis of how Part D plans have changed from 2006 to 2007 Analysis of problems faced by Part D since its roll-out, and the identification of possible improvement areas going forward Identification of how key issues such as the dual eligible patient population and drug sourcing in the donut hole are shaping Part D evolution

Highlights of this title:
Uptake into Part D has been strong, and despite the size and complexity of the program, patient satisfaction has been relatively high. The program faced a number of teething problems during roll-out, which have largely been resolved (e.g. IT issues); however, there are still a number of issues that havent been remedied. A significant factor to impact Part D is the way that plan providers have handled patients covered by both Medicare and Medicaid. Providing these dual eligibles with adequate coverage has been a significant challenge, particularly during the roll-out of the program. The choice facing Part D beneficiaries about where to source drugs when they enter the gap in coverage in Part D programs (termed the donut hole) is also impacting plan providers and patients, since patient choice in this situation has a significant impact on market dynamics.

Reasons to order your copy:
Gain a clear understanding of how Part D has evolved since its roll-out in January 2006 Understand the problems that Part D has faced, together with identifying areas for improvement Gain insight into the key issues that are shaping Part D currently and in the future

Pipeline And Commercial Insight: Influenza Vaccines - Pandemic Threat Revitalizes The Sector

press@researchandmarkets.com — Fri, 27 Apr 2007 11:06:07 GMT

The influenza vaccine market, sized at approximately $2.2 billion in 2006, yields many challenges. Demand is highly variable, and only large players are able to cope with the need for annual updates and the costly manufacturing process. However, driven by the increasing pandemic threat, the market is growing fast and is predicted to more than double in size by 2016.

Scope of this title:
Strategic analysis of the current influenza market across the US, Japan, France, Germany, Italy, Spain and the UK and of key companies in the sector Thorough assessment of underlying commercial and clinical influencers shaping the influenza vaccine market Patient-based forecasts for the influenza vaccine market taking into account recommended vaccination groups and coverage rates in the 7 major markets In-depth comparative analysis of both seasonal and pandemic influenza vaccine pipeline candidates and discussion of their future potential

Highlights of this title:
The demand for influenza vaccines is highly variable and the time window for the vaccination is limited to just a few months per year. This, in combination with the need for annual updates and the long planning cycles required due to the lengthy egg-based manufacturing process, makes the flu vaccine market a highly challenging sector. The pandemic threat has acted as an important driver for the seasonal vaccine market. Rising public awareness of influenza has increased the demand for seasonal vaccination. Government funding provided for pandemic research is also benefiting seasonal vaccine development through technology transfer. With Novartis cell-based Optaflu currently awaiting EU approval and ProteinSciences baculovirus-based FluBlØk in phase III, new production techniques available are shaping up to change market dynamics. Further advances include adjuvanted vaccines, and, in earlier development stages, DNA- and universal vaccine candidates.

Reasons to order your copy:
Review the clinical and commercial factors driv

Pipeline Insight: Antithrombotics - Reaching The Untreated Prophylaxis Market

press@researchandmarkets.com — Fri, 27 Apr 2007 11:06:05 GMT

Novel oral anticoagulants and antiplatelet agents will have a profound impact on the antithrombotics market We expect Bayers rivaroxaban and Sankyo/Eli Lillys prasugrel to achieve blockbuster status Parenteral anticoagulants are not expected to be large revenue generators, due to low clinical unmet...

Obesity Therapeutics: Understanding Market Dynamics (Presentation)

press@researchandmarkets.com — Fri, 27 Apr 2007 11:05:59 GMT

Obesity Therapeutics: Understanding Market Dynamics, a presentation given at the Obesity Drug Development Summit in July 2006.

Scope of this title:
An overview of the obesity epidemic given by our Healthcare team. Lists of current obesity drugs and those in development.

Highlights of this title:
It is estimated that 44% of US adults and 29% of European adults are currently considered Dieters.

Reasons to order your copy:
Understand the current state and growth rates of obesity. Assess the treatment options for obesity including drug types.

Early-Stage Pharmaceutical Marketing Budgets: Preparing for Product Launch

press@researchandmarkets.com — Thu, 22 Mar 2007 17:21:17 GMT

Early-Stage Pharmaceutical Marketing Budgets: Preparing for Product Launch analyzes the commercialization budgets of 14 brands during pre-clinical development, Phase I and Phase II Learn where and when top pharmaceutical and biotech companies dedicate key commercialization dollars to adequately...

State of the Pharmaceutical Industry, 2007

press@researchandmarkets.com — Mon, 12 Mar 2007 15:13:43 GMT

“Change is in the air for pharmaceutical companies as governments and judiciary work to strike a balance between ongoing business practices, patent laws, and drug price controls 2007 will almost certainly end with harsher regulatory and legislative environments There has never been a greater need...

Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2006

press@researchandmarkets.com — Mon, 12 Mar 2007 14:55:32 GMT

Introduction: Implementation and refinement of existing pricing and reimbursement initiatives throughout the major pharmaceutical markets continued to be a major theme in the fourth quarter of 2006 In the United States, preparations continued for the second year of the Medicare Part D prescription...

The Anemia Market: Biogenerics and Second-Generation Products Drive Change

press@researchandmarkets.com — Mon, 12 Mar 2007 14:43:58 GMT

The availability of recombinant biologic agents has revolutionized the treatment of anemia and has created a market with a small number of players However, the inconvenient administration and high prices of these biologic agents represent an opportunity for companies to enter this market with...

The Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007

press@researchandmarkets.com — Mon, 26 Feb 2007 16:52:11 GMT

With a market size of US$14 5 billion in 2005 and an anticipated value of US$16 5 billion in 2006, the neurodegenerative market represents a valuable, fast-growing opportunity in the pharma/biotech industry An increase in the number of aged people, increased life expectancy, unmet clinical needs...

Developing the High-Performance Market Research Function

press@researchandmarkets.com — Tue, 20 Feb 2007 17:14:33 GMT

Market research departments increasingly face this challenge to their primary roles: evolving from providers of support-level data to highly-valued business advisors for strategic decision-making This comprehensive report examines how dozens of companies have created exceptional market research...

European Autoimmune Diseases Therapeutics Markets

press@researchandmarkets.com — Mon, 05 Feb 2007 15:47:16 GMT

This Frost & Sullivan research service titled European Autoimmune Disease Therapeutics Market provides an overview of current treatment options, drugs in pipeline and technological advancements in the market It also a complete analysis of key market drivers, restraints and revenues involved in the...